Alvin Wong Biography and Net Worth

Insider of Puma Biotechnology

Dr. Wong was named Chief Scientific Officer of Puma Biotechnology in June 2021. He joined Puma in March 2013 and in August 2017 he was appointed Senior Vice President, Clinical Science and Pharmacology. In April 2021, he assumed responsibility for Translational Biology and Biometrics, including Biostatistics, Programming and Data Management, in addition to Clinical Science/Pharmacology. Dr. Wong served as Clinical Lead of the successful FDA submissions of neratinib for the extended adjuvant treatment of patients with early stage HER2-positive breast cancer and subsequent submission of neratinib for patients with HER2-positive metastatic breast cancer. From 2007 to 2013, Dr. Wong was Senior Director of Clinical development at Proteolix, Inc. (acquired by Onyx) where he managed studies in multiple myeloma and supported the approval of Kyprolis®. Previously, he held positions in Clinical Pharmacology and Pharmacovigilance at Novacea, where he was the project leader of AQ4N and clinical pharmacology lead for oral vinorelbine and DN101, and in drug safety at Genentech, where he contributed to the successful submissions of Herceptin® for HER2-positive breast cancer, Rituxan® for patients with non-Hodgkin’s Lymphoma and Avastin® for patients with advanced colorectal cancer.

Dr. Wong earned his Doctor of Pharmacy degree from the University of California at San Francisco (UCSF). He was also a Clinical Professor at the UCSF School of Pharmacy from 1976 to 1996.

What is Alvin F. Wong's net worth?: The estimated net worth of Alvin F. Wong is at least $278,927.76 as of January 3rd, 2024. Dr. Wong owns 98,214 shares of Puma Biotechnology stock worth more than $278,928 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Wong may own. Learn More about Alvin F. Wong's net worth.
How do I contact Alvin F. Wong?: The corporate mailing address for Dr. Wong and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Alvin F. Wong's contact information.
Has Alvin F. Wong been buying or selling shares of Puma Biotechnology?: Alvin F. Wong has not been actively trading shares of Puma Biotechnology within the last three months. Most recently, Alvin F. Wong sold 7,733 shares of the business's stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $4.49, for a transaction totalling $34,721.17. Following the completion of the sale, the insider now directly owns 98,214 shares of the company's stock, valued at $440,980.86. Learn More on Alvin F. Wong's trading history.
Who are Puma Biotechnology's active insiders?: Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Douglas Hunt (Insider), Ann Miller (Director), Maximo Nougues (CFO), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?: During the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 174,074 shares worth more than $667,379.98. The most recent insider tranaction occured on August, 12th when Director Michael Patrick Miller sold 23,358 shares worth more than $81,519.42. Insiders at Puma Biotechnology own 23.7% of the company. Learn More about insider trades at Puma Biotechnology.
Information on this page was last updated on 8/12/2024.

Alvin F. Wong Insider Trading History at Puma Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2024	Sell	7,733	$4.49	$34,721.17	98,214
7/3/2023	Sell	6,938	$3.31	$22,964.78	105,947
6/2/2023	Sell	269	$3.45	$928.05	112,885
1/3/2023	Sell	3,460	$4.18	$14,462.80	54,553
6/2/2022	Sell	587	$1.92	$1,127.04	61,447
12/2/2021	Sell	1,131	$2.91	$3,291.21

Alvin F. Wong Buying and Selling Activity at Puma Biotechnology

Puma Biotechnology Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Today's Range

Now: $2.84

$2.66

$2.86

50 Day Range

MA: $2.75

$2.42

$3.30

2 Week Range

Now: $2.84

$2.22

$7.73

Volume

270,751 shs

Average Volume

565,949 shs

Market Capitalization

$139.42 million

P/E Ratio

5.92

Dividend Yield

N/A

Beta

1.09

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>